Map Parkinson brain immune activity
- Trial ID
- NCT05205291
- Official Title
- Molecular Imaging of LPS-induced Microglial Activation in Parkinson's Disease (PD). A TSPO PET-MR Imaging Study
- Goal
- Map Parkinson brain immune activity
- Status
- RECRUITING
- Sponsor
- University of Exeter
- Study Type
- OBSERVATIONAL
- Enrollment
- 30 participants
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, REM Sleep Behavior Disorder (iRBD)
- Interventions
- Lipopolysaccharide, PET/MR with [11C]PBR28
Plain-Language Summary
Goal: to see where and how much brain immune cells called microglia become active in Parkinson's disease and in people with REM sleep behavior disorder, by provoking a short, controlled immune response and imaging the brain. Approach: participants receive a small, controlled dose of lipopolysaccharide to trigger innate immune activation, then have PET/MR scans with the tracer [11C]PBR28 which binds the TSPO protein on activated microglia so higher PET signal indicates more neuroinflammation; the protocol includes people who are drug-naïve or who are on stable dopaminergic therapy. Eligibility: looking for adults mainly 50 to 85 years old (iRBD arm may include 40+), including people with Parkinson's, people with iRBD, or healthy controls, who are cognitively intact, free of active inflammatory or major medical conditions, able to undergo MRI and arterial sampling, and who are not low-affinity binders for the PET tracer.
Locations
- University of Exeter, Exeter, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Lipopolysaccharide. Goal: to see where and how much brain immune cells called microglia become active in Parkinson's disease and in people with REM sleep behavior disorder, by provoking a short, controlled immune response and imaging the brain. Approach: participants receive a small, controlled dose of lipopolysaccharide to trigger innate immune activation, then have PET/MR scans with the tracer [11C]PBR28 which binds the TSPO protein on activated microglia so higher PET signal indicates more neuroinflammation; the protocol includes people who are drug-naïve or who are on stable dopaminergic therapy. Eligibility: looking for adults mainly 50 to 85 years old (iRBD arm may include 40+), including people with Parkinson's, people with iRBD, or healthy controls, who are cognitively intact, free of active inflammatory or major medical conditions, able to undergo MRI and arterial sampling, and who are not low-affinity binders for the PET tracer.
- Who can participate?
- Participants must be between 50 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years and 6 months.